000274040 001__ 274040
000274040 005__ 20250119000253.0
000274040 0247_ $$2doi$$a10.3389/fnins.2024.1502246
000274040 0247_ $$2pmid$$apmid:39726830
000274040 0247_ $$2pmc$$apmc:PMC11669673
000274040 0247_ $$2ISSN$$a1662-4548
000274040 0247_ $$2ISSN$$a1662-453X
000274040 0247_ $$2altmetric$$aaltmetric:172562134
000274040 037__ $$aDZNE-2025-00021
000274040 041__ $$aEnglish
000274040 082__ $$a610
000274040 1001_ $$aKnab, Felix$$b0
000274040 245__ $$aThe cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.
000274040 260__ $$aLausanne$$bFrontiers Research Foundation$$c2024
000274040 3367_ $$2DRIVER$$aarticle
000274040 3367_ $$2DataCite$$aOutput Types/Journal article
000274040 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736338671_683
000274040 3367_ $$2BibTeX$$aARTICLE
000274040 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274040 3367_ $$00$$2EndNote$$aJournal Article
000274040 520__ $$aExtracellular vesicles are easily accessible in various biofluids and allow the assessment of disease-related changes in the proteome. This has made them a promising target for biomarker studies, especially in the field of neurodegeneration where access to diseased tissue is very limited. Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson's disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.In this study, we used induced pluripotent stem cells derived from a patient with Parkinson's disease carrying the LRRK2 G2019S mutation and an isogenic gene-corrected control to generate human dopaminergic neurons. We isolated extracellular vesicles and neuronal cell lysates and characterized their proteomic signature using data-independent acquisition proteomics. Then, we performed differential expression analysis to identify dysregulated proteins in the mutated line. We used Metascape and gene ontology enrichment analysis on the dysregulated proteomes to identify changes in associated functional networks.We identified 595 significantly differentially regulated proteins in extracellular vesicles and 3,205 in cell lysates. We visualized functionally relevant protein-protein interaction networks and identified key regulators within the dysregulated proteomes. Using gene ontology, we found a close association with biological processes relevant to neurodegeneration and Parkinson's disease. Finally, we focused on proteins that were dysregulated in both the extracellular and cellular proteomes. We provide a list of ten biomarker candidates that are functionally relevant to neurodegeneration and linked to LRRK2-associated pathology, for example, the sonic hedgehog signaling molecule, a protein that has tightly been linked to LRRK2-related disruption of cilia function.In conclusion, we characterized the cellular and extracellular proteome of dopaminergic neurons carrying the LRRK2 G2019S mutation and proposed an experimentally based list of biomarker candidates for future studies.
000274040 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000274040 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000274040 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274040 650_7 $$2Other$$aLRRK2
000274040 650_7 $$2Other$$aParkinson’s disease
000274040 650_7 $$2Other$$abiomarker
000274040 650_7 $$2Other$$aextracellular vesicle
000274040 650_7 $$2Other$$ainduced pluripotent stem cell
000274040 7001_ $$0P:(DE-2719)2811633$$aGuaitoli, Giambattista$$b1$$udzne
000274040 7001_ $$aJarboui, Mohamed Ali$$b2
000274040 7001_ $$0P:(DE-2719)2811552$$avon Zweydorf, Felix$$b3$$udzne
000274040 7001_ $$aIsik, Fatma Busra$$b4
000274040 7001_ $$aKlose, Franziska$$b5
000274040 7001_ $$aRajkumar, Anto Praveen$$b6
000274040 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b7$$udzne
000274040 7001_ $$0P:(DE-2719)2811291$$aGloeckner, Christian Johannes$$b8$$eLast author$$udzne
000274040 773__ $$0PERI:(DE-600)2411902-7$$a10.3389/fnins.2024.1502246$$gVol. 18, p. 1502246$$p1502246$$tFrontiers in neuroscience$$v18$$x1662-4548$$y2024
000274040 8564_ $$uhttps://pub.dzne.de/record/274040/files/DZNE-2025-00021.pdf$$yOpenAccess
000274040 8564_ $$uhttps://pub.dzne.de/record/274040/files/DZNE-2025-00021.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274040 909CO $$ooai:pub.dzne.de:274040$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274040 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000274040 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811552$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000274040 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000274040 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811291$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000274040 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000274040 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000274040 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-26
000274040 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000274040 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROSCI-SWITZ : 2022$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:19:45Z
000274040 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:19:45Z
000274040 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274040 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:19:45Z
000274040 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000274040 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000274040 9201_ $$0I:(DE-2719)1210007$$kAG Gloeckner$$lFunctional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases$$x0
000274040 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000274040 980__ $$ajournal
000274040 980__ $$aVDB
000274040 980__ $$aUNRESTRICTED
000274040 980__ $$aI:(DE-2719)1210007
000274040 980__ $$aI:(DE-2719)1210000
000274040 9801_ $$aFullTexts